Alphatec (NASDAQ:ATEC) Trading 9.3% Higher

Alphatec Holdings Inc (NASDAQ:ATEC)’s stock price traded up 9.3% during mid-day trading on Wednesday . The stock traded as high as $4.72 and last traded at $4.69, 421,157 shares traded hands during mid-day trading. An increase of 5% from the average session volume of 402,036 shares. The stock had previously closed at $4.29.

Several research analysts have recently issued reports on the company. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Zacks Investment Research upgraded Gerdau from a “sell” rating to a “hold” rating in a research note on Monday, May 13th.

The business’s 50 day simple moving average is $4.37. The company has a debt-to-equity ratio of 4.79, a current ratio of 2.31 and a quick ratio of 1.18. The firm has a market cap of $208.05 million, a price-to-earnings ratio of -8.09 and a beta of 1.51.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, May 9th. The medical technology company reported ($0.20) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.20). The company had revenue of $24.56 million for the quarter, compared to analysts’ expectations of $24.00 million. Alphatec had a negative return on equity of 156.32% and a negative net margin of 42.16%. On average, equities analysts expect that Alphatec Holdings Inc will post -0.65 earnings per share for the current year.

In other news, EVP Craig E. Hunsaker sold 50,000 shares of Alphatec stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $4.50, for a total transaction of $225,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 34.32% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Penn Capital Management Co. Inc. purchased a new position in shares of Alphatec in the first quarter valued at $1,261,000. Royce & Associates LP grew its position in Alphatec by 728.6% in the 1st quarter. Royce & Associates LP now owns 290,000 shares of the medical technology company’s stock valued at $768,000 after buying an additional 255,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Alphatec by 8.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock valued at $219,000 after buying an additional 7,705 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its position in Alphatec by 49.2% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 29,063 shares of the medical technology company’s stock valued at $67,000 after buying an additional 9,579 shares in the last quarter. Finally, Suntrust Banks Inc. bought a new position in Alphatec in the 4th quarter valued at about $58,000. 14.82% of the stock is owned by hedge funds and other institutional investors.

About Alphatec (NASDAQ:ATEC)

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Read More: Resistance Level

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.